South Korea’s major pharmaceutical company GC Biopharma Corp. announced on Monday that it shipped the initial volume of Alygro, its immunoglobulin blood product to enter the US market.
Alyglo, which received approval from the US Food and Drug Administration (FDA) in December last year, is the primary humoral immunodeficiency (PHI) treatment.
(Courtesy of GC Biopharma) The US is the world’s largest immunoglobin market with a value of around 16 trillion won ($11.6 billion).
The initial shipment will reach patients through specialty pharmacies across the US by mid-July.
GC Biopharma has been actively preparing for its US launch.
It secured a key partnership on July 1 with a major US Pharmacy Benefit Manager (PBM) to list Alyglo covered on their formularies (lists of approved drugs).
The company signed contracts with reputable specialty pharmacies and distributors to build a strong distribution network.
The company aims to $50 million in Alyglo sales this year and projects annual growth to capture a market share in the US.